Background:
Delta-like ligand 4 (Dll4) is a Notch ligand that is upregulated by hypoxia and vascular endothelial growth factor-A (VEGF-A) and is reported to have a role in tumor angiogenesis. Evidence from xenograft studies suggests that inhibiting Dll4âNotch signalling may overcome resistance to anti-VEGF therapy. The aim of this study was to characterise the expression of Dll4 in colon cancer and to assess whether it is associated with markers of hypoxia and prognosis.
Method:
In all, 177 colon cancers were represented in tissue microarrays. Immunohistochemistry was performed using validated antibodies against Dll4, VEGF, hypoxia-inducible factor (HIF)-1
α
, HIF-2
α
, prolyl hydroxylase (PHD)1, PHD2, PHD3 and carbonic anhydrase 9 (CA9).
Results:
The expression of Dll4 was observed preferentially in the endothelium of 71% (125 out of 175) of colon cancers, but not in the endothelium adjacent to normal mucosa (none out of 107,
P
<0.0001). The expression of VEGF was significantly associated with HIF-2
α
(
P
<0.0001) and Dll4 (
P
=0.010). Only HIF-2
α
had a significant multivariate prognostic effect (hazard ratio 1.61, 95% confidence interval 1.01â2.57). Delta-like ligand 4 was also expressed by neoplastic cells, particularly neoplastic goblet cells.
Conclusion:
Endothelial expression of Dll4 is not a prognostic factor, but is significantly associated with VEGF. Assessing endothelial Dll4 expression may be critical in predicting response to anti-VEGF therapies.